SAVA Q3 2019 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena

SAVACassava Sciences, Inc.

$115M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$104

Gross Profit

$5250.0% margin

Operating Income

-$779,000-749038.5% margin

Net Income

-$697,000-670192.3% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$730,000

Free Cash Flow

-$730,000

Stock-Based Comp.

$319,000

Balance Sheet

Total Assets

$18M

Total Liabilities

$930,000

Stockholders' Equity

$17M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$104	$0	—
Gross Profit	$52	-$436	+111.9%
Operating Income	-$779,000	-$1M	+39.3%
Net Income	-$697,000	-$1M	+45.0%